HeartCare-B (06609.HK) Surges Over 11% on Executive Share Purchase and A-Share IPO Progress

According to the Zhongtong Wealth Management APP, HeartCare-B (06609) surged over 11%. As of press time, it rose by 11.17%, trading at HK$60.7 with a turnover of HK$7.6481 million.

On the news front, on December 12, 2025, HeartCare -B announced that it plans to sell 1 million domestically-owned shares to Zhang Han at a discount of 1.10%, raising HK$43.25 million net. CITIC Securities pointed out that after the completion of the transaction, it will further increase the company's liquid cash reserves. This cash is expected to be fully utilized by the end of 2028 for investment/acquisitions in the medical device industry, which is expected to expand the company’s product portfolio and support its long-term sustainable growth.

The bank believes that the company's senior executives’ acquisition of company shares with their own funds demonstrates the management's confidence in the progress of the company’s A-share IPO and its medium- to long-term strategic development. Previously, on September 15, 2025, the company published an article on its official WeChat account stating that the launch event for the company’s A-share IPO was successfully held, indicating that the company is expected to further enhance capital market liquidity through an A-share IPO in the future. In addition, the company is actively promoting the medical device registration process for its invasive brain-computer interface products, with the first human clinical enrollment expected to be completed by the end of 2026.